Iq-ai Ltd Regulatory News (IQAI)

19 July 2023

IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics Installs IB Nimble™ For MCW Bone Mets Treatment

Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), today announced that its handheld application, IB Nimble, has been adopted by Orthopedic Department of the Medical College of Wisconsin for use in their treatment of bone metastases. The handheld app provides real-time collaboration amongst multi-disciplinary teams securely and asynchronously.

Designed initially by Dr. Joseph Bovi, MD, Professor of Radiation Oncology and Neurosurgery at MCW, for brain metastases, IB Nimble's base functionality has been enhanced to accommodate any disease or pathology that requires multi-disciplinary input. The clinical benefit of providing optimized treatments faster to patients with brain metastases is now being afforded to patients with bone mets.

"This marks the first installation for use in diseases sites other than brain metastases and demonstrates that IB Nimble is ready for widespread deployment," said Josh McComack, IB's Director of Software Engineering.

--ENDS-

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

About Imaging Biometrics® LLC:  IB is a wholly-owned subsidiary of IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.